BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211030
DTSTAMP:20260515T220447
CREATED:20210617T150512Z
LAST-MODIFIED:20210628T073150Z
UID:30590-1635206400-1635551999@www.pharmajournalist.com
SUMMARY:4th Targeted Protein Degradation Summit
DESCRIPTION:As the most comprehensive\, industry-focused and ‘must-attend’ event in the field\, the 4th Targeted Protein Degradation Summit returns to once again explore the latest approaches\, perspectives\, and data-drive case studies that will continue to advance PROTACs\, molecular glues\, and other degrader modalities towards clinical success. \nWith 70+ world-class speakers and over 500 senior attendees from around the globe\, join the largest community of protein degradation experts for a deep dive into clinical development progress\, lessons learnt and novel strategies to develop safe\, selective and effective PROTACs\, molecular glues\, lysosomal degradation\, autophagy-mediated degraders as well as uncovering novel degrader modalities and approaches for oncology and beyond. \nKey Highlights: \n\nEvaluate the exclusive updates of ongoing clinical trials to accelerate towards the first clinically approved therapy with insights from Kymera Therapeutics\, Arvinas\, Nurix Therapeutics & Bristol Myers Squibb\nDeep dive into the methodologies of enhancing target engagement by improving target specificity\, uncovering strategies to find novel ligases and modelling of covalency to develop next generation degraders with insights from Eli Lilly\, FogPharma\, GSK & Janssen\nReview the plethora of disease indications that are being targeted by PROTACs and molecular glues including Alzheimers\, Parkinsons\, COVID-19 and AML with insights from Bristol Myers Squibb\, Progenra & Origami Therapeutics\nExplore the different approaches to penetrating the blood brain barrier\, comparing and contrasting the discovery\, development and optimization of PROTACs and molecular glues for neurodegenerative indications with insights from C4 Therapeutics & Progenra\nOutline the core mechanisms of PROTAC resistance and the approaches to overcoming this to successfully progress through preclinical and clinical studies with insights from University of Dundee\, Ranok Therapeutics & Captor Therapeutics\n\nTo know more about 4th Targeted Protein Degradation Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-targeted-protein-degradation-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T220447
CREATED:20210622T141849Z
LAST-MODIFIED:20210622T141849Z
UID:30663-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:5th Complement-based Drug Development Summit
DESCRIPTION:Discover the Intricacies of Complement Pathways to Accelerate Clinical Validation & Maximize Complement-Targeting in the Pan-Disease Setting \nBuilt with Alexion\, Apellis and Annexon\, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industry dedicated forum to maximize complement-targeting in the pan-disease setting. \nWith pivotal clinical readouts poised to be released in 2021\, this year’s summit will once again unite thought leaders in complement-based drug development. \n \nExpect to be involved in interactive discussions on: \n\nHow dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5\nPreclinical and clinical pipeline progress of diverse drug modalities\, including gene therapy approaches\, small molecule inhibitors\, antibodies\, protease inhibitors\, nucleic acids & more!\nLeveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics\nAddressing clinical challenges of complement-targeted therapeutic sequencing\, combinations and timing of administration\nExpanding the clinical utility of complement inhibitors across rare diseases\, as well as autoimmune\, ophthalmic\, neurological and cancer settings\n\nNew for this year\, you’ll have a two-tracked agenda with more speakers\, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent\, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets! \nTo know more about 5th Complement-based Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/5th-complement-based-drug-development-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T220447
CREATED:20210701T113342Z
LAST-MODIFIED:20210701T113448Z
UID:30764-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:6th Annual Neoantigen Based Therapies US Summit 2021
DESCRIPTION:Your Comprehensive End-to-End Guide to Transforming the Clinical Development of Cell & Vaccine Based Neoantigen Therapies \nThe growth and comeback of the neoantigen space has resulted in an abundance of new data\, innovative insights and valuable lessons learned on how to drive meaningful clinical responses\, all of which will be shared at the 6th Neoantigen Based Therapies US Summit. \nExploring the potential of shared neoantigens vs. personalized neoantigens and optimizing the selection and identification of the best and most immunogenic neoantigens\, the world’s leaders from the likes for BioNTech\, Gritstone\, Advaxis\, Genocea\, Treos Bio and many more will gather at the only 3-day summit focused on the exploding field of Neoantigen based Therapies. \nJoin over 100 experts to discuss what the optimal control\, clinical and combination trial designs should look like\, advances in accurate and robust validation assays\, and explore how we can manufacture effectively and at scale both shared and personalized neoantigen based therapies. \nLeave this meeting equipped with new collaborations across pharma\, biotech and academia\, and learn how to supercharge vaccine and cell immunotherapies for solid tumors and beyond. \nTo know more about 6th Annual Neoantigen Based Therapies US Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/6th-annual-neoantigen-based-therapies-us-summit-2021/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T220447
CREATED:20210715T092520Z
LAST-MODIFIED:20210715T092520Z
UID:30937-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:2nd Supply Chain and Logistics for Cell Therapies Summit
DESCRIPTION:At the virtual 2nd Supply Chain and Logistics for Cell Therapies Summit\, your community will gather to network\, share exclusive insights in case-study led sessions\, and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale. \nImplement robust\, patient-centric supply chains for clinical to commercial readiness: \n\nBuild your supply strategyand manage risk and forecasting at scale by designing for growth\nMaximize your cloud-based and integrated systems and hear the latest innovations in chain of identity\n\nManage materials\, external manufacturing and facility design\n\nOptimize patient care with best practice guidelines and integrated platforms: \n\nUnderstand clinical requirementsand develop clinical strategies for seamless therapeutic delivery\nDiscuss and establish industry best practices and understand which standard practices can apply across a range of cell modalities\n\nMaintain product quality at scale for seamless delivery of autologous and allogeneic therapies: \n\nOptimize front-end processes and develop patient care organisations\nDiscuss quality control and site audits to ensure best standard of care and product quality\n\nFind out more >>> https://ter.li/mt5mh1
URL:https://www.pharmajournalist.com/event/2nd-supply-chain-and-logistics-for-cell-therapies-summit/
LOCATION:Virtual Event | Eastern Time
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T220447
CREATED:20210809T145746Z
LAST-MODIFIED:20210809T145746Z
UID:31270-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:9th Advanced RWE Applications in Pharma
DESCRIPTION:Real-world evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real world into their development programs\, drug developers can now improve their clinical trial success by identifying and retaining suitable patients through increased patient stratification. \nThese are exciting times to reunite at the 9th Advanced Real-World Evidence Applications in Pharma to discuss the efforts to advance real-world evidence’s effective generation and utilization. \nThe stage is set for a collaborative discussion platform bringing together you and other stakeholders from functions across clinical development\, RWE\, RWD\, Data Science\, Regulatory Affairs\, Medical Affairs\, HEOR\, and many more! \nJoin us in October to overcome critical challenges in generating and implementing real-world evidence to enhance clinical R&D\, support regulatory submission and decision-making\, and ultimately drive commercial success. \nClick here to download the event guide for the full agenda\n\nWhat’s New in 2021? \n2020 was an exciting year for real-world data (RWD) and real-world evidence (RWE) experts within pharma and biotech. The FDA’s high-profile acceptance of RWD as part of their review for COVID-19 treatments and vaccines for emergency use authorization was a big moment for the industry. This is now energizing RWD and RWE into R&D and clinical activities – expediting novel treatments for patients and substantially reducing drug developers’ R&D spend. \nHowever\, major questions still need answers urgently. The 9th Advanced Real-World Evidence Applications in Pharma will return in October 2021 to delve into the core industry challenges\, including: \n\nAssessing the global regulatory environment for future RWE application\nAdvanced data acquisition and analytics to enable your R&D and clinically informed decision making\nLeverage RWE in your clinical activities – from patient selection to synthetic trial arm\nHow to create a robust\, regulatory-compliant RWE framework and data package for your successful IND filing\nMaximizing your product lifecycle through a comprehensive observational data program\nEstablishing pre-competitive collaboration to deepen your understanding of diseases\, offering patients a personalized and effective treatment through RWE & RWD\n\nBook now to save up to $750
URL:https://www.pharmajournalist.com/event/9th-advanced-rwe-applications-in-pharma/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211027
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T220447
CREATED:20200618T111721Z
LAST-MODIFIED:20210729T114826Z
UID:25936-1635292800-1635465599@www.pharmajournalist.com
SUMMARY:Protein Engineering Global USA
DESCRIPTION:The series brings together a global audience and global lineup of biocatalyst and protein modifications specialists to share how to implement the new technologies. With the applications growing across pharmaceutical\, flavour & fragrance\, consumer goods\, food & beverage and agrochemical sectors\, we have created a protein and enzyme engineering platform that will allow the community to improve capabilities to industrialize sustainable enzyme products and increase product efficiency globally. \nUnderstand the challenges and requirements of the industry in their internal R&D projects to support scale-up processes\, next-generation mutant library screening\, or knowledge of machine learning and AI to optimize biocatalysts for industrial applications. \nExpand your commercial opportunities and market growth by learning what new industry sectors are seeing the benefit of enzyme engineering to synthesize unprecedented molecules of interest and engage and network with these industries to form new third-party collaborations\, allowing you to advance your market growth. \nDemonstrate advancements in your service capabilities by actively promoting the work of your technical teams through bespoke webinar opportunities\, presentations\, and interactive discussion with the industry. \nWe are delighted to be hosting Protein Engineering Global 2 miles from San Jose International Airport SJC\, and offer a special bedroom rate to the attendees of the Protein Engineering Congress: \n$199 + tax per room per night – Please call +1 408-453-6200 and quote Kisaco research/Protein Engineering. \nDownload agenda: www.proteinengineeringglobal.com/
URL:https://www.pharmajournalist.com/event/protein-engineering-congress/
LOCATION:Holiday inn San Jose- Silicon Valley\, 1350 North 1st Street\, San Jose\, CA\, 95112\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR